Korea Investment CORP Has $94.27 Million Stake in Pfizer Inc. $PFE

Key Points

• Korea Investment CORP has reduced its stake in Pfizer Inc. by 13.0%, selling 556,393 shares to end up with approximately 3.72 million shares valued at $94.3 million.
• Pfizer recently declared a quarterly dividend of $0.43, representing an annualized yield of 6.8%, with a payout ratio of 91.49%.
• Analysts have set a consensus price target of $28.12 for Pfizer, with mixed ratings—one sell, eleven holds, five buys, and two strong buys.

Korea Investment CORP reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 13.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 3,720,238 shares of the biopharmaceutical company's stock after selling 556,393 shares during the quarter. Korea Investment CORP owned approximately 0.07% of Pfizer worth $94,271,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in PFE. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter worth approximately $27,000. Gould Capital LLC increased its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter worth approximately $27,000. North Capital Inc. bought a new position in Pfizer in the 1st quarter worth approximately $28,000. Finally, Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth approximately $28,000. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PFE. Wolfe Research lifted their price objective on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. HSBC decreased their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. The Goldman Sachs Group upped their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.2250 during midday trading on Tuesday, hitting $25.2950. 29,134,298 shares of the company were exchanged, compared to its average volume of 45,102,056. The firm has a 50 day simple moving average of $24.64 and a 200-day simple moving average of $24.41. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The firm has a market cap of $143.82 billion, a P/E ratio of 13.45, a PEG ratio of 0.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period last year, the firm posted $0.60 EPS. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.